Dr. Mitchell Ho is an Investigator and Chief of the Antibody Therapy Section in the Laboratory of Molecular Biology at the National Cancer Institute (NCI), National Institutes of Health. Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NCI working on immunotoxin therapy of cancer. Research in Dr. Ho's laboratory at the NCI aims to develop novel antibody therapies for liver cancer as well as other cancers. Dr. Ho is a recipient of the NCI Director's Intramural Innovation Award for Principal Investigators, the Mesothelioma Applied Research Foundation Grant Award, and the Ovarian Cancer Research Fund Individual Investigator Award.

Research in Dr. Ho's laboratory at the NCI aims to develop novel antibody therapies for liver cancer as well as other cancers.